COVID-19: a case for inhibiting IL-17?

Abstract

IL-17 inhibition boasts an impressive safety history, is immunologically plausible as a strategy to prevent ARDS in COVID-19, and is widely available. Here we discuss why we think that a clinical trial of a drug in this class could be a logical addition to the effort to find effective therapies.

The number of cases and deaths due to coronavirus disease 2019 (COVID-19) are staggering. Currently, there is no specific treatment available for this disease and off-label investigations of many FDAapproved therapeutics, including remdesivir, hydroxychloroquine, azithromycin, and tocilizumab, in an effort to demonstrate improved outcomes, are ongoing. Here we discuss the current literature describing known contributions of interleukin-17 (IL-17) to COVID-19-related acute respiratory distress syndrome (ARDS) and present arguments for consideration of the use of anti-IL-17 therapy in COVID-19.

COVID-19 is caused by SARS-CoV-2, a betacoronavirus closely related to MERS-CoV and SARS-CoV, the causative agents of Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), respectively. These viruses cause high mortality, most often resulting from progressive inflammatory viral pneumonia that clinically culminates in ARDS¹. COVID-19 seems to follow a similar pattern, with 81% of fatal cases diagnosed with ARDS2. In consideration of this, a recent correspondence in The Lancet suggests that all patients with COVID-19 should be screened for hyperinflammation in order to identify who would benefit from targeted immunosuppression or immunomodulation to prevent acute lung injury (ALI)³.

IL-17 (formally, IL-17A) is the most well-known member of a multifunctional cytokine family. Its predominant role seems to be dependent on where the cytokine is expressed (gut, lung or skin) and what the precipitating trigger is. These two factors appear to influence whether the prevailing effect of its expression is protective or leads to a detrimental hyper-inflammatory state. Demonstrating the protective effects, mice lacking functional IL-17 receptor (Il17a^−/−) signaling were shown to be more susceptible than wild type mice to secondary pneumonia caused by Staphylococcus aureus following infection with influenza A4. However, influenza A challenge of Il17a^−/− mice resulted in less histological inflammation of the lungs and lower mortality compared to wild type mice, revealing the mixed immunopathologic effects⁵. For MERS-CoV, SARS-CoV and SARS-CoV-2, the severity of disease was shown to positively correlate with levels of IL-17 and other T_H17-related pro-inflammatory cytokines such as IL-1, IL-6, IL-15 TNF, and IFNγ^1,6.

IL-17 inhibition has been adopted as a common and successful strategy to reduce the injury associated with inflammatory autoimmune diseases including psoriasis and psoriatic arthritis. Dysregulation of T_H17 cells and production of IL-17 in the skin, synovial space, and endothelium promotes the production of downstream proinflammatory molecules such as IL-1β, TNF, IL-6, and neutrophil chemoattractants such as IL-8, CCL-20 and CCL-2. Recruited neutrophils then produce IL-6 and reactive oxygen species, leading to characteristic skin lesions and joint destruction. Histologically, a hallmark feature of psoriasis, especially the pustular form, is accumulation of neutrophilic pustules and neutrophilic debris in the epidermis.

Like psoriasis, in ALI and ARDS there is a disruption of the balance of proinflammatory and anti-inflammatory cytokines. The shift to proinflammatory cytokine production in the lungs is pathologically characterized by diffuse alveolar damage with numerous neutrophils and protein rich edema in the alveolar space. In ARDS, IL-17 augments the destruction of the lung parenchyma through maladaptive neutrophil recruitment, by stimulating the production of pro-inflammatory mediators and through the prevention of apoptosis due to the induction of granulocyte-colony stimulating factor expression⁷.

The excessive production of IL-17 that has been observed in patients with ALI/ARDS has been recapitulated in mouse models of ALI/ARDS with lipopolysaccharide (LPS)-induced ALI, allowing a better characterization of the pathophysiology of these conditions as well as providing insights into possible treatments. Increased IL-17 levels in mice with LPSinduced ALI correlate with increased lung injury scores, greater protein-rich inflammatory lung infiltration, and decreased overall survival. Furthermore, addition of exogenous IL-17 further exacerbated LPS-induced production of TNF, IL1β, IL-6 and CXCL2, revealing the role of IL-17 as a key upstream modulator of the inflammatory pathway. In the same study, mice genetically deficient in IL-17 or those that received anti-IL-17 antibodies demonstrated improved survival, less lung infiltration and better lung pathology scores following LPS challenge⁸.

Congruently, a retrospective analysis of IL-17 gene polymorphisms in patients with ARDS revealed that patients with a polymorphism that resulted in attenuated IL-17 production had an increased 30-day survival, whereas a genetic polymorphism that resulted in producing more IL-17 had a decreased survival9. Similar T_H1 and T_H17 proinflammatory cytokine profiles are observed in patients with MERS and in patients with COVID-19, including elevated IL-17^1,6. In a small sample of patients with COVID-19, the elevation of IL-17 in addition to 14 other distinct cytokines were positively correlated with an increased Murray score for lung injury. Assessing the performance of this cytokine as a biomarker of disease, IL-17 had an area under the receiver operating curve score of 0.926, indicating a very good ability to distinguish between severe and mild COVID-19 cases^1,6. Taken together, these analyses of patients with coronaviruses-induced lung disease suggest that IL-17 can serve as both a biomarker of disease severity and a potential target of therapy to mitigate the damage of COVID-19 particularly to the lung.

It should be noted that COVID-19 mortality is also associated with myocarditis in the setting of ARDS. A T_H17-dominant immunophenotype has been reported to drive more severe viral myocarditis¹⁰. This suggests that potential anti-IL-17 therapy may play a role in decreasing morbidity and mortality related to COVID-19 virally induced myocarditis.

The complex role of IL-17 in the immune system is nuanced and incompletely understood. However, in the setting of ALI/ARDS triggered by betacoronaviruses, IL-17 appears to be markedly elevated, with evidence that it contributes to immunopathology^1,6. Data is limited by the novelty of COVID-19, the sudden appearance of these viruses and the limited number of patients with documented SARS and MERS that were studied. Better substantiated is the relatively low risk profile for infections in patients receiving IL-17 inhibition therapy, as such therapies have been in wide use for over four years.

Three commercially available options exist: secukinumab (human monoclonal antibody against IL-17), ixekizumab (humanized monoclonal antibody against IL-17) and brodalumab (human monoclonal antibody against the IL-17 receptor). Both secukinumab and ixekizumab are approved for psoriasis, psoriatic arthritis and ankylosing spondylitis, brodalumab is approved for the treatment of psoriasis alone. These three drugs are supplied with warnings about an increased risk of infections. Compared to placebo, clinical trials showed a moderate increase in upper respiratory infections (URIs) for patients treated with secukinumab, a similar number of URIs for patients treated with ixekizumab, whereas treatment with brodalumab resulted in a lower rate of URIs . The risk of serious infections is unchanged or low over the short term. Therefore, using these drugs in the acute setting of COVID-19 should not carry an increased risk of secondary infections.

[H1] Conclusion

Experimental immunomodulatory treatment of COVID-19 is ongoing, both in controlled clinical trials and also in an uncontrolled fashion on a compassionate basis. Immunomodulation is not a novel idea as a means to improve outcomes of COVID-19 ARDS. Indeed, several clinical trials investigating inhibitors of the IL-1-receptor (anakinra) and the IL-6 receptor (tocilizumab) are ongoing, as are debates about the effectiveness or harm of corticosteroids. By targeting IL-17, which operates “upstream” of both IL-1and IL-6 and results in a reduction of neutrophil recruitment, several factors known to play major roles in ARDS would be inhibited. Therefore, IL-17 presents itself as a plausible target.